Regeneron Announces New Presentation Schedule
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has shared a recent update regarding its schedule at the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will now present at 7:00 a.m. ET on the designated day for attendees and investors.
Webcast Availability
This presentation will be streamed live, and interested parties can easily access the webcast through the "Investors & Media" section of Regeneron's official website. Following the event, recorded replays alongside transcripts will be available online, ensuring that investors can revisit any part of the presentation they find important.
About Regeneron's Mission
Regeneron stands at the forefront as a biotechnology leader, committed to developing medicines that serve vital needs for patients suffering from serious health conditions. With a foundation built by physician-scientists, the company excels in turning scientific discoveries from their labs into tangible therapies.
Innovative Approaches in Medicine
The company’s expansive pipeline is focused on addressing a diverse range of diseases, whether they are related to the eyes, allergies, or various cancers. Regeneron is also advancing research in fields such as cardiovascular health, metabolism, and neurological conditions, highlighting their commitment to enhance patient health across multiple dimensions.
Technological Advancements
Regeneron harnesses innovative technology like VelociSuite, an operation that crafts optimized fully human antibodies and bispecific antibodies. The company leverages its proprietary tools and insights from its Genetics Center to spot new treatment targets while bolstering their drug development processes.
Community Engagement and Information Access
Those interested in the latest from Regeneron are encouraged to explore their website for further details. Additionally, investors can connect with the company on various social media platforms including LinkedIn, Instagram, and Facebook to stay up-to-date with ongoing projects, research, and breakthroughs.
Contact Information for Investors
If you have inquiries regarding investor relations, you may reach out to Ryan Crowe at 914-847-8790 or contact him via email at ryan.crowe@regeneron.com.
Frequently Asked Questions
What is the updated time for Regeneron's presentation?
The updated presentation time is now set for 7:00 a.m. ET at the Morgan Stanley 23rd Annual Global Healthcare Conference.
How can I access the presentation?
The presentation will be available via live webcast on Regeneron’s “Investors & Media” webpage.
What types of treatments does Regeneron focus on?
Regeneron develops treatments for various diseases, including those affecting the eyes, cancer, and cardiovascular health, among others.
What technologies does Regeneron employ in its research?
The company utilizes proprietary technology like VelociSuite to develop new medicines and therapeutic approaches.
Who can I contact for investor relations?
You can contact Ryan Crowe at 914-847-8790 or email him at ryan.crowe@regeneron.com.